BTK inhibitors in the treatment of B-call lymphoma

Chaired by Dr Anthony Mato

Featuring Dr Deborah Stephens

Featuring Professor Martin Dreyling

Welcome to this expert-led webcast with global experts discussing Bruton's tyrosine kinase (BTK) inhibitors in the treatment of B-cell malignancies.

This program reviews key data presented at the ASH 2021 Annual Meeting, highlighting the advances being made that have the potential to shape future patient care for people with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Audience

This program is designed for, but not limited to, hematologists, oncologists, and other healthcare professionals involved in the management of patients with hematologic malignancies globally.

Learning objectives

After participating in the program, learners will be able to:

Compare the efficacy and safety profiles of approved and emerging BTK inhibitors in the treatment of MCL, CLL and SLL
Explain how these profiles inform current practice and could shape future patient care
Incorporate BTK inhibitors in the clinical management of MCL, CLL and SLL

Educational Grant

This activity is supported by an educational grant from Lilly.

Accreditation

In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME.